Aminologics CoLtd (Korea) Performance
| 074430 Stock | KRW 913.00 13.00 1.40% |
Aminologics CoLtd has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.0704, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Aminologics CoLtd are expected to decrease at a much lower rate. During the bear market, Aminologics CoLtd is likely to outperform the market. Aminologics CoLtd right now shows a risk of 1.27%. Please confirm Aminologics CoLtd semi deviation, coefficient of variation, and the relationship between the mean deviation and downside deviation , to decide if Aminologics CoLtd will be following its price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Aminologics CoLtd are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, Aminologics CoLtd is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Total Cashflows From Investing Activities | -632.4 M |
Aminologics |
Aminologics CoLtd Relative Risk vs. Return Landscape
If you would invest 90,200 in Aminologics CoLtd on December 24, 2024 and sell it today you would earn a total of 1,100 from holding Aminologics CoLtd or generate 1.22% return on investment over 90 days. Aminologics CoLtd is generating 0.0292% of daily returns and assumes 1.2699% volatility on return distribution over the 90 days horizon. Simply put, 11% of stocks are less volatile than Aminologics, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Aminologics CoLtd Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aminologics CoLtd's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aminologics CoLtd, and traders can use it to determine the average amount a Aminologics CoLtd's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.023
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 074430 |
Estimated Market Risk
| 1.27 actual daily | 11 89% of assets are more volatile |
Expected Return
| 0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Aminologics CoLtd is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aminologics CoLtd by adding it to a well-diversified portfolio.
Aminologics CoLtd Fundamentals Growth
Aminologics Stock prices reflect investors' perceptions of the future prospects and financial health of Aminologics CoLtd, and Aminologics CoLtd fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aminologics Stock performance.
| Return On Equity | 9.11 | |||
| Return On Asset | 0.0325 | |||
| Profit Margin | 0.36 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 238.08 B | |||
| Shares Outstanding | 94.06 M | |||
| Price To Sales | 8.45 X | |||
| Revenue | 22.85 B | |||
| EBITDA | 3.45 B | |||
| Cash And Equivalents | 8.86 B | |||
| Cash Per Share | 264.10 X | |||
| Total Debt | 468.03 M | |||
| Debt To Equity | 0.03 % | |||
| Cash Flow From Operations | 935.52 M | |||
| Total Asset | 65.24 B | |||
| Retained Earnings | (78.81 B) | |||
| Current Asset | 27.46 B | |||
| Current Liabilities | 5.67 B | |||
About Aminologics CoLtd Performance
By analyzing Aminologics CoLtd's fundamental ratios, stakeholders can gain valuable insights into Aminologics CoLtd's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Aminologics CoLtd has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Aminologics CoLtd has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
,Ltd., a specialty amino acid provider, develops a range of amino-acid-based raw materials for pharmaceutical and fine chemical industries in South Korea. ,Ltd. was founded in 1997 and is headquartered in Seoul, South Korea. AMINOLOGICS is traded on Korean Securities Dealers Automated Quotations in South Korea.Things to note about Aminologics CoLtd performance evaluation
Checking the ongoing alerts about Aminologics CoLtd for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aminologics CoLtd help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| About 31.0% of the company shares are owned by insiders or employees |
- Analyzing Aminologics CoLtd's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aminologics CoLtd's stock is overvalued or undervalued compared to its peers.
- Examining Aminologics CoLtd's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aminologics CoLtd's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aminologics CoLtd's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aminologics CoLtd's stock. These opinions can provide insight into Aminologics CoLtd's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Aminologics Stock analysis
When running Aminologics CoLtd's price analysis, check to measure Aminologics CoLtd's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aminologics CoLtd is operating at the current time. Most of Aminologics CoLtd's value examination focuses on studying past and present price action to predict the probability of Aminologics CoLtd's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aminologics CoLtd's price. Additionally, you may evaluate how the addition of Aminologics CoLtd to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |